CMECECNECPE

Deep Remission: Top-Down Treatment Strategies and Real-World Data in Patients with UC: An Interactive and Innovative Case Series

Author(s)/Faculty: Arthur A. Kornbluth, MD ; Maria T Abreu, MD; Miguel Regueiro, MD, FACP, FACG, AGAF
Source: Healio - Gastroenterology Education Lab
Type: MultimediaArticles/Items: 2
Release Date: 8/21/2017Expiration Date: 6/8/2018
Credit Type: CME / CNE / PharmacyNumber of Credits: 1.5
Cost: FreeProvider: CME Outfitters

Ulcerative colitis (UC) is an inflammatory bowel disease with a progressive course characterized by exacerbations and remissions. Traditionally, the goals of therapy for UC have entailed resolution of clinical symptoms such as rectal bleeding, bloody diarrhea, abdominal cramps, pain, and fatigue. However, treatment goals for UC have evolved to a treat-to-target strategy with targets such as mucosal/endoscopic healing, histologic healing, or deep remission (i.e., clinical, biochemical, and endoscopic remission) with the objective of preventing structural damage and disability. Conventional therapies have not been uniformly effective in achieving these aims, necessitating augmentation with steroids and carrying adverse risk often requiring discontinuation.

There has been an exponential growth in the pursuits of better targeted therapy to optimize IBD clinical outcomes. IBD therapies that explore new targets and inflammatory pathways are emerging to address the current treatment gaps observed with conventional and biologic therapies.

In this CME Outfitters symposium, expert faculty will guide learners through patient cases using an interactive infographic to explain the importance of initiating early targeted biologic therapy and provide evidence-based strategies to take action to achieve sustained remission and long-term clinical outcomes.

CME Information

page 1 of 5